Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03463252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 13, 2021 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Secondary endpoints: details revised at 1 of 1 entryv4
  2. Primary completion date: Dec 30, 2019 to Dec 30, 2025
    • Study completion date: Dec 31, 2020 to Dec 30, 2030
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.
Trial Details
NCT Number NCT03463252
Lead Sponsor West China Second University Hospital
Conditions
(from sponsor)		 Endometrial Cancer, Atypical Endometrial Hyperplasia
Related terms Endometrial Hyperplasia, Endometrial Neoplasms
Enrollment 224 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov